Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand.
Chaicharn DeerochanawongRungroj KrittayaphongJack Garcia Uranga RomanoNicolai R RheeUnchalee PermsuwanPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Compared to the SoC treatment, adding liraglutide at the current cost is not cost-effective at the local WTP. People with T2D with ASCVD would have the most potential gain from adding liraglutide treatment compared to other populations.